Alpha Teknova (NASDAQ:TKNO) Announces Earnings Results

Alpha Teknova (NASDAQ:TKNO) posted its quarterly earnings results on Wednesday. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01, FiscalAI reports. Alpha Teknova had a negative net margin of 41.07% and a negative return on equity of 23.68%. The business had revenue of $11.08 million during the quarter, compared to analysts’ expectations of $10.23 million.

Here are the key takeaways from Alpha Teknova’s conference call:

• Revenue rose 13% YoY, led by an 85% increase in Clinical Solutions, with Q1 topping $11M and more large orders (> $25k) indicating stronger customer execution.
• Management is increasing commercial spend by roughly $2M annually to hire sales and marketing talent and boost lead generation, expecting this to start lifting revenue by early 2027 and targeting ~20% revenue growth in 2027.
• Operational improvements—tripling high-volume batch sizes, installing an automated aseptic filling line, and digitizing ~90% of paper batch records—should improve scalability, reduce labor per unit, and support margin expansion.
• The company remains unprofitable with a Q1 net loss of $4.6M, adjusted EBITDA of negative $2.0M, and Q1 free cash outflow of $3.6M, and while full?year FCF is expected to be < $10M, cash usage continues.

Alpha Teknova Stock Performance

Shares of TKNO stock opened at $4.00 on Friday. The company has a current ratio of 4.58, a quick ratio of 3.64 and a debt-to-equity ratio of 0.19. The firm has a fifty day simple moving average of $2.88 and a two-hundred day simple moving average of $3.58. Alpha Teknova has a 12 month low of $1.91 and a 12 month high of $7.48. The firm has a market capitalization of $214.44 million, a PE ratio of -12.50 and a beta of 0.47.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Teknova in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $8.00.

Insider Buying and Selling at Alpha Teknova

In related news, CEO Stephen Gunstream acquired 26,000 shares of the company’s stock in a transaction on Friday, March 6th. The shares were acquired at an average cost of $2.15 per share, for a total transaction of $55,900.00. Following the purchase, the chief executive officer owned 269,497 shares in the company, valued at approximately $579,418.55. The trade was a 10.68% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 12.50% of the company’s stock.

Hedge Funds Weigh In On Alpha Teknova

Several hedge funds have recently modified their holdings of TKNO. Susquehanna International Group LLP grew its holdings in shares of Alpha Teknova by 25.0% in the third quarter. Susquehanna International Group LLP now owns 16,206 shares of the company’s stock valued at $100,000 after acquiring an additional 3,246 shares in the last quarter. Larson Financial Group LLC lifted its holdings in Alpha Teknova by 58.5% during the third quarter. Larson Financial Group LLC now owns 9,387 shares of the company’s stock worth $58,000 after acquiring an additional 3,464 shares during the period. JPMorgan Chase & Co. boosted its position in Alpha Teknova by 123.1% in the second quarter. JPMorgan Chase & Co. now owns 8,163 shares of the company’s stock worth $40,000 after purchasing an additional 4,504 shares during the last quarter. Bridgeway Capital Management LLC boosted its position in Alpha Teknova by 7.9% in the third quarter. Bridgeway Capital Management LLC now owns 80,900 shares of the company’s stock worth $501,000 after purchasing an additional 5,900 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Alpha Teknova in the 2nd quarter valued at $29,000. Institutional investors own 13.81% of the company’s stock.

Alpha Teknova Company Profile

Alpha Teknova, Inc (NASDAQ: TKNO) is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.

The company’s portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.